PD-1/PD-L1 Expression Levels and Prognostic Significance in Chronic Lymphocytic Leukemia

Overall survival rates were 69.1% in PD-1+ vs 79% in PD-1- groups and 75% in PD-L1+ vs 73.6% in the PD-L1- group in the 60th month (p=0.723, p=0.849 respectively).

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Purpose:In this study, we aimed to evaluate expression levels of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) and the effects on prognosis in chronic lymphocytic leukemia (CLL).

📊

Key Findings & Data:Patients and Methods:92 patients who had flow cytometry from peripheral blood at the time of diagnosis were included in this study.

💡

Conclusion & Impact:Overall survival rates were 69.1% in PD-1+ vs 79% in PD-1- groups and 75% in PD-L1+ vs 73.6% in the PD-L1- group in the 60th month (p=0.723, p=0.849 respectively).

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:programmed cell death 1 · programmed cell death ligand 1 · chronic lymphocytic leukemia

Abstract

Purpose:In this study, we aimed to evaluate expression levels of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) and the effects on prognosis in chronic lymphocytic leukemia (CLL). Patients and Methods:92 patients who had flow cytometry from peripheral blood at the time of diagnosis were included in this study. The presence of PD-1/PD-L1 staining in 20% and above in lymphocytes was considered positive. Results:Median follow-up was 31 (1-114) months. PD-1 positivity was detected in 44 (47.8%), and PD-L1 positivity in 8 (8.7%) patients. The mean PD-1 level was 22.13% ± 15.39, and PD-L1 level was 8.4% ± 13.12 in all cohort. Overall survival rates were 69.1% in PD-1+ vs 79% in PD-1- groups and 75% in PD-L1+ vs 73.6% in the PD-L1- group in the 60th month (p=0.723, p=0.849 respectively). After first line treatment, partial response or better was observed in 18 (85.7%) patients in the PD-1- group and in 10 (71.4%) patients in the PD-1+ group (p=0.401). Median progression-free survival was 16 months [95% CI, 10.68-21.31] in the PD-1+ group, and 18 months [95% CI, 5.23-30.76] in the PD-1- group (p=0.432). In PD-1+ patients, time to next treatment was 2 (0-25) months, while in PD-1- patients it was determined as 7 (0-80) months (p=0.372). Conclusion:PD-1 expression was detected on lymphocytes in peripheral blood in CLL, however PD-L1 expression level was quite low. There was no clear effect of PD-1 and PD-L1 positivity on prognosis

Özet

Amaç:Çalışmamızda, kronik lenfositik lösemide (KLL) programlı hücre ölümü 1 (PD-1) ve programlı hücre ölümü ligandı 1 (PD-L1) ekspresyon düzeylerinin belirlenmesi ve prognoz üzerine etkilerinin değerlendirilmesi amaçlandı. Hastalar ve Yöntem:Kliniğimizde takip edilmiş ve tanı anında periferik kandan akım sitometrisi çalışılmış 92 hasta bu çalışmaya dahil edildi. Lenfositlerde %20 ve üzeri hücrede PD-1/PD-L1 boyanma varlığı pozitif olarak kabul edildi Bulgular:Hastaların ortanca takip süresi 31 (1-114) aydı. PD-1 pozitifliği hastaların 44’ünde (%47.8), PD-L1 pozitifliği ise 8’inde (%8.7) tespit edildi. Tüm kohortta ortalama PD-1 düzeyi %22.13±15.39, PD-L1 düzeyi ise %8.4±13.12 olarak saptandı. Ortanca genel sağkalıma ulaşılamamış olmakla birlikte 60. ayda PD-1 pozitif hastaların %69.1’i hayattayken, PD-1 negatif grupta bu oran %79’du (p=0.723). Yine 60. ayda PD-L1 pozitif hastaların %75’i hayattayken, PD-L1 negatif grupta bu oran %73.6’ydı (p=0.849). PD-1 negatif grupta ilk dizi tedavi sonrası kısmi yanıt ve üstü 18 (%85.7) hastada mevcutken, PD-1 pozitif grupta 10 (%71.4) hastada mevcuttu (p=0.401). Ortanca progresyonsuz sağkalım, PD-1 pozitif grupta 16 ay [ %95 GA,10.68-21.31] iken PD-1 negatif grupta 18 ay [%95 GA, 5.23-30.76] olarak tespit edildi (p=0.432). PD-1 pozitif hastalarda ikinci dizi tedaviye geçiş süresi 2 (0-25) ay iken, PD-1 negatif hastalarda 7 (0-80) ay olarak tespit edildi (p=0.372). Sonuç:KLL’de periferik kanda lenfositler üzerinde PD-1 ekspresyonu tespit edilmiş olup PD-L1 ekspresyon düzeyi oldukça düşük düzeyde saptandı. PD-1 ve PD-L1 pozitifliğinin prognoz üzerinde net bir etkisi gözlemlenmedi

Keywords

programmed cell death 1 programmed cell death ligand 1 chronic lymphocytic leukemia

🔖

Cite This Article

GEDÜK, A., MEHTAP, Ö., ATEŞOĞLU, E. B., TARKUN, P., DEMİRSOY, E. T., MENGÜÇ, M. U., ÜNAL, S., MERSİN, S., HACIHANEFİOĞLU, A., BURHANOĞLU, T., GACAR, G. (2021). PD-1/PD-L1 Expression Levels and Prognostic Significance in Chronic Lymphocytic Leukemia. Acıbadem Üniversitesi Sağlık Bilimleri Dergisi, Cilt: 12 - Sayı: 2, 197–203. https://ajindex.com/articles/162650

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (15)

Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005; 352:804-15
Milne K, Sturrock B, Chevassut T. Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived. Curr Oncol Rep. 2020;22:36
Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018;94:121-8
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64
Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365-9
Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027-34
Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2:261-8
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704
Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007 Jul;19(7):813-24
Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-44
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of antiPD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54
Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-35
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC,Gutierrez M, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372(4):311-9
Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, et al. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. Blood. 2017;129:3419-27
Brusa D, Serra S, Coscia M, Rossi D, D’Arena G, Laurenti L, et al. The PD-1/PD-L1 axis contributes to T-cel